BioNTech Acquires Biotheus to Enhance Cancer Therapies

BioNTech SE (BNTX) has released an update.

BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its oncology strategy by securing global rights to an investigational bispecific antibody, BNT327/PM8002. This acquisition is expected to enhance BioNTech’s capabilities in developing next-generation cancer therapies, potentially setting a new standard of care for solid tumors. The transaction, which includes up to $150 million in milestone payments, is anticipated to close in the first quarter of 2025.

For further insights into BNTX stock, check out TipRanks’ Stock Analysis page.